Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (471-480 of 908) with videos related to

Pageof 91
Sort By:
European Journal of Heart Failure|July 19, 2016
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programmeKevin Damman, Scott D Solomon, Marc A Pfeffer, et al.
JAMA|September 18, 2003
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trialChristopher M O'Connor, Michael W Dunne, Marc A Pfeffer, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
Circulation|June 28, 2006
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trialScott D Solomon, Madeline M Rice, Kathleen A Jablonski, et al.
The New England Journal of Medicine|February 17, 2005
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventionScott D Solomon, John J V McMurray, Marc A Pfeffer, et al.
European Heart Journal|November 7, 2008
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programmeAlain Cohen-Solal, John J V McMurray, Karl Swedberg, et al.
The New England Journal of Medicine|March 11, 2011
Irbesartan in patients with atrial fibrillation, Salim Yusuf, Jeff S Healey, et al.
European Journal of Heart Failure|May 27, 2020
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Xavier Rossello, Stuart J Pocock, et al.
Journal of Medical Internet Research|August 14, 2020
Excess Patient Visits for Cough and Pulmonary Disease at a Large US Health System in the Months Prior to the COVID-19 Pandemic: Time-Series AnalysisJoann G Elmore, Pin-Chieh Wang, Kathleen F Kerr, et al.
American Heart Journal|February 15, 2001
Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysisY Aikawa, L Rohde, J Plehn, et al.
Pageof 91

Showing results (471-480 of 908) with videos related to

Sort By:
Pageof 91
European Journal of Heart Failure|July 19, 2016
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programmeKevin Damman, Scott D Solomon, Marc A Pfeffer, et al.
JAMA|September 18, 2003
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trialChristopher M O'Connor, Michael W Dunne, Marc A Pfeffer, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
Circulation|June 28, 2006
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trialScott D Solomon, Madeline M Rice, Kathleen A Jablonski, et al.
The New England Journal of Medicine|February 17, 2005
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventionScott D Solomon, John J V McMurray, Marc A Pfeffer, et al.
European Heart Journal|November 7, 2008
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programmeAlain Cohen-Solal, John J V McMurray, Karl Swedberg, et al.
The New England Journal of Medicine|March 11, 2011
Irbesartan in patients with atrial fibrillation, Salim Yusuf, Jeff S Healey, et al.
European Journal of Heart Failure|May 27, 2020
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Xavier Rossello, Stuart J Pocock, et al.
Journal of Medical Internet Research|August 14, 2020
Excess Patient Visits for Cough and Pulmonary Disease at a Large US Health System in the Months Prior to the COVID-19 Pandemic: Time-Series AnalysisJoann G Elmore, Pin-Chieh Wang, Kathleen F Kerr, et al.
American Heart Journal|February 15, 2001
Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysisY Aikawa, L Rohde, J Plehn, et al.
Pageof 91